Colombo, Nicoletta
Zaccarelli, Eleonora
Baldoni, Alessandra
Frezzini, Simona
Scambia, Giovanni
Palluzzi, Eleonora
Tognon, Germana
Lissoni, Andrea A.
Rubino, Daniela
Ferrero, Annamaria
Farina, Gabriella
Negri, Emanuele
Pesenti Gritti, Angela
Galli, Francesca
Biagioli, Elena
Rulli, Eliana
Poli, Davide
Gerardi, Chiara
Torri, Valter
Fossati, Roldano
D‘Incalci, Maurizio
Funding for this research was provided by:
Partial unconditional fundings from Roche and PharmaMar Fundings from IRCCS Mario Negri Institute
Article History
Received: 28 February 2019
Revised: 27 August 2019
Accepted: 30 August 2019
First Online: 20 September 2019
Competing interests
: Nicoletta Colombo: Honoraria from Pharma Mar, Roche and other companies. Maurizio D’Incalci: Honoraria from Pharma Mar, Roche and other companies, Editorial Board Member of the British Journal of Cancer. The remaining authors declare no competing interests.
: Approved by the Coordinating Ethics Committee of the European Institute of Oncology, Milan (comitato.etico@ieo.it) on the 11 November 2012 (representative Dr Atanasio Nonis). The study was conducted in accordance with the International Conference on Harmonisation/Good Clinical Practice [ICH/GCP] and patients had to have signed written informed consent before randomisation.
: Partial unconditional funding from Roche and Pharma Mar. Other funding from Mario Negri Institute IRCCS.
: The manuscript does not contain any individual person’s data in any form (individual details, images or videos).
: Data supporting the results reported can be found at Mario Negri Institute IRCCS for Pharmacologic Research, Milan. Data sharing is encouraged, and data are available on request to the corresponding author.